Cancer Care Ontario | Action Cancer Ontario

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

145 Results

Guidelines and Advice

Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Status: Current
ID: GL SCT-8

Oct 2017

Guidelines and Advice

Systemic therapy for the treatment of adult patients with lower-risk myelodysplastic syndromes

Status: In-Review
ID: 6-13

Mar 2018

Guidelines and Advice

Recommendations for the Delivery of Psychosocial Oncology Services in Ontario

Status: Current

Dec 1969

Guidelines and Advice

Position Statements for Nursing Practice in Cancer Care

Status: Current
Version: 2

Dec 1969

Guidelines and Advice

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Status: Current
ID: GL END 2-31

Jul 2018

Guidelines and Advice

Safety Considerations for the Implementation of Subcutaneous Rituximab Formulation

Status: Current
Version: 1

Dec 1969

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Dec 1969

Guidelines and Advice

Cancer Care Ontario Beyond-Use Date Recommendations Report

Status: Current
ID: N/A
Version: 1

Mar 2018

Guidelines and Advice

Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline

Status: In-Review
ID: 7-14
Version: 3

Dec 1969

Guidelines and Advice

Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario

Status: Current
ID: N/A
Version: N/A

Mar 2019

Guidelines and Advice

Enhancing the Delivery of Take-Home Cancer Drugs in Ontario

Status: Current

Mar 2019

Guidelines and Advice

Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario

Status: Current
ID: GL 5-3ORG
Version: 2

Dec 1969

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Systemic therapy for the treatment of adult patients with lower-risk myelodysplastic syndromes

Recommendations for the Delivery of Psychosocial Oncology Services in Ontario

Position Statements for Nursing Practice in Cancer Care

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Safety Considerations for the Implementation of Subcutaneous Rituximab Formulation

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Cancer Care Ontario Beyond-Use Date Recommendations Report

Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline

Follow-Up Model of Care for Cancer Survivors: Recommendations for the Delivery of Follow-up Care for Cancer Survivors in Ontario

Enhancing the Delivery of Take-Home Cancer Drugs in Ontario

Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario

Pages